MP0112 (0.04 mg) [clinicaltrials_resource:NCT01086761/group/B1]
Single 0.04 mg intravitreal injection of MP0112 in the study eye.
group [clinicaltrials_vocabulary:group]
NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/0208cb524ed872b5924e7a76b77d1a27]NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/28cac9e048a5ab701b70797333fef96d]NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/49e51287b0fe5a2002fa01fda404dfba]NCT01086761 measurement [clinicaltrials_resource:NCT01086761/measurement/8b8a5ec7e4f316a301edc91e8887967d]
group id [clinicaltrials_vocabulary:group-id]
MP0112 (0.04 mg) [clinicaltrials_resource:NCT01086761/group/B1]
Single 0.04 mg intravitreal injection of MP0112 in the study eye.
Bio2RDF identifier
NCT01086761/group/B1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT01086761/group/B1
group id [clinicaltrials_vocabulary:group-id]
description
Single 0.04 mg intravitreal injection of MP0112 in the study eye.
@en
identifier
clinicaltrials_resource:NCT01086761/group/B1
title
MP0112 (0.04 mg)
@en
type
label
MP0112 (0.04 mg) [clinicaltrials_resource:NCT01086761/group/B1]
@en